KRAS G12S
Clinical trials for KRAS G12S explained in plain language.
Never miss a new study
Get alerted when new KRAS G12S trials appear
Sign up with your email to follow new studies for KRAS G12S, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets multiple KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…
Matched conditions: KRAS G12S
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for pancreatic cancer patients: experimental immunotherapy offered outside clinical trial
Disease control AVAILABLEThis program provides access to an experimental immunotherapy called ELI-002 7P for patients with a specific type of pancreatic cancer (with KRAS or NRAS mutations) who are at high risk of the cancer coming back after surgery. It is for patients who have no other good treatment o…
Matched conditions: KRAS G12S
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC